AKT Combination Increased PFS in Metastatic HR-Positive/HER2-Negative Breast Cancer

(MedPage Today) -- CHICAGO -- Progression-free survival (PFS) in metastatic hormone receptor (HR)-positive breast cancer more than doubled with the AKT inhibitor ipatasertib added to fulvestrant after first-line CDK4/6 inhibition, a randomized...